F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture.

Akrevia’s Aklusion platform enables biological molecules such as antibodies, cytokines and chemokines to remain inactive until reaching the tumor microenvironment. Akrevia licensed the technology from City of Hope (Duarte, Calif.) and Thomas Jefferson University (Philadelphia, Pa.)...